The
global pulmonary arterial hypertension market is expected to rise
proportionate to the rise in the number of heart failures. Pulmonary
arterial hypertension is characterized by restrained blood flow via
the pulmonary arteries, which leads to a constant increase in
pulmonary vascular resistance and finally failure of the right side
of the heart. PAH is one of five groups of pulmonary hypertension, as
described by the World Health Organization (WHO). PAH develops due to
the narrowing, blocking, and thickening of the pulmonary arteries.
Browse
Full Global Pulmonary Arterial Hypertension Market Report With
Complete TOC @
http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html
Advanced
treatment of PAH includes prostacyclin and prostacyclin analogs,
phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor
antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators.
This leading therapy is aimed towards the symptoms of PAH and is not
directed at the fundamental cause of PAH. In addition to the
aforementioned classification of drugs, there are some other drugs
prescribed to patients suffering from PAH, such as diuretics, calcium
channel blockers, anticoagulants, and digoxin.
The
pulmonary arterial hypertension (PAH) market was valued at US$4.04
billion in 2013 and is expected reach US$5.19 billion in 2020,
expanding at a CAGR of 2.3% between 2014 and 2020.
Uptravi:
A New Drug Application in Patients with Pulmonary Arterial
Hypertension
Categorized
on the basis of substantially applicable drug categories, the global
pulmonary arterial hypertension (PAH) market has been segregated into
prostacyclin analogs and prostacyclin, endothelin receptor
antagonists (ERAs) and soluble guanylate cyclase (sGC) stimulators.
Prostacyclin and prostacyclin analogs were the foremost to be
medically endorsed by the U.S. FDA to treat PAH. Presently,
epoprostenol Veletri and Flolan, treprostinil (Tyvaso, Remodulin, and
Orenitram), and iloprost (Ventavis) are the three primary drugs in
this category, and are widely used in the treatment for patients with
PAH. A new drug called Uptravi, which is an assorted IP prostacyclin
antagonist, is predicted to come to the fore by 2016. This new drug
is expected to augment the growth of the market for prostacyclin
analogs and prostacyclin through the forecast period from 2014 to
2020.
Browse
Full Presss Release Report:
http://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics-market.htm
Opsumit:
The Highest Selling Pulmonary Arterial Hypertension Drug
Endothelin
receptor antagonists (ERAs) that disrupt the interaction between
endothelin receptors and endothelin have materialized as one of the
primary segments in the treatment of PAH. Tracleer (bosentan) is the
foremost FDA-certified ERA. Opsumit (macitentan) and
Letairis/Volibris (ambrisentan) are some other certified ERAs for the
treatment of PAH. Among these, Opsumit was certified by the European
Commission and the U.S. FDA in December 2013. Opsumit is predicted to
materialize as the highest selling PAH drug by the end of 2020.
Tracleer is set to be off-patent in Europe and the U.S. in 2017 and
2015, respectively. Patent termination of Tracleer is expected to
constitute a big setback in the advancement of the ERAs market from
2014 to 2020.
Adempas:
The only Certified Stimulator by the U.S. FDA to Treat Pulmonary
Hypertension
Adcirca
(tadalafil) from Eli Lilly/United Therapeutics Corporation and
Revatio (sildenafil) from Pfizer, Inc., are the FDA-certified PDE-5
inhibitors used for the treatment of PAH. Adempas (riociguat) is the
only approved sGC blockage used for the treatment of PAH. Adempas is
devised for the treatment of PAH by stimulation of nitric oxide
receptor sGC, which causes vasodilation, relieving the pressure on
arterial walls. Adempas was first certified by the U.S. FDA in
October 2013. Throughout the forecast period from 2014 to 2020,
riociguat would undergo extreme competition from drugs such as
treprostinil and macitentan, as all of them are meant for oral
application.
Leading
players in the global pulmonary arterial hypertension (PAH) market
include United Therapeutics Corporation, Gilead Sciences, GSK Plc,
and Actelion Pharmaceuticals, Ltd. Among these, Actelion Pharma held
the biggest share in the global PAH market in 2013 thanks to its
top-selling product, Tracleer (bosentan).
Request
a Brochure of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1181
About Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our
experienced team of Analysts, Researchers, and Consultants, use
proprietary data sources and various tools and techniques to gather,
and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Mr.
Nachiket
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment